The synthetic oligonucleotide-based antagonist, IMO-8400, which targets endolysosomal TLR7, TLR8, and TLR9, was demonstrated to be effective in xenograft models of WM and DLBCL harboring MYD88 mutations, but it is not clear why this inhibitor is more effective in cell harboring MYD88L265P compared to those lacking MYD88 mutation. Here, MYD88 is linked to diffuse large B-cell lymphoma.